Mending a broken heart: current strategies and limitations of cell-based therapy

Lee Chuen Liew, Beatrice Xuan Ho and Boon-Seng Soh

Abstract
The versatility of pluripotent stem cells, attributable to their unlimited self-renewal capacity and plasticity, has sparked considerable interest for potential application in regenerative medicine. Over the past decade, the concept of replenishing the lost cardiomyocytes, the crux of the matter in ischemic heart disease, with pluripotent stem cell-derived cardiomyocytes (PSC-CM) has been validated with promising pre-clinical results. Nevertheless, clinical translation was hampered in by limitations such as immature cardiac properties, long-term engraftment, graft-associated arrhythmias, immunogenicity, and risk of tumorigenicity. The continuous progress of stem cell-based cardiac therapy, incorporated with tissue engineering strategies and delivery of cardio-protective exosomes, provides an optimistic outlook on the development of curative treatment for heart failure. This review provides an overview and current status of stem cell-based therapy for heart regeneration, with particular focus on the use of PSC-CM. In addition, we also highlight the associated challenges in clinical application and discuss the potential strategies in developing successful cardiac-regenerative therapy.

Keywords: Ischemic heart disease, Cell-based therapy, Pluripotent stem cells, Cardiomyocytes, Exosome

Introduction
Ischemic heart disease, the most common type of cardiovascular disease, is characterized by the restriction of blood flow to the heart muscle that results from the plaque build-up in the arteries. This obstruction of coronary arteries limits the oxygen supply to the heart tissue and thus causes irreversible death of cardiomyocytes (myocardial infarction). As the disease progresses, especially if left untreated, the expansion of the infarcted zone will impair the function of the left ventricle, which would eventually lead to heart failure. The current therapeutic options available, including pharmaceutical drugs, such as angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, and angiotensin receptors blockers, are mainly symptomatic treatments that could merely alleviate the manifestation of the disease. Similarly, although cardiac revascularization therapy with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), as well as the use of cardiac implantable electronic devices could improve the patient survival and quality of life, they have been ineffective in preventing the disease progression. While heart transplantation is thought to be the only curative treatment for patients with end-stage heart failure, the shortage of organ donors that limit the number of possible heart transplants and the associated post transplant complications makes this treatment inapplicable as yet.

Cardiovascular research has largely been focused on cell-based therapy for myocardial repair, with particular emphasis on replacement and/or restoration of the damaged myocardium. For the past two decades, immense efforts have been put into experimenting a myriad of transplantable cell types for their use in cardiac regeneration. These include skeletal myoblasts, bone marrow mononuclear cells (BM-MNC), hematopoietic stem cells (HSC), endothelial progenitor cells (EPC), mesenchymal
stem cells (MSC), and pluripotent stem cell (PSC)-derived cardiomyocytes (CM) (PSC-CM) (Fig. 1). While seemingly favorable outcomes do come into view, no one ideal cell type has yet to emerge. This review aims to evaluate the existing state of cell-based therapy for heart disease, with a particular focus on PSC-CM. Herein, we also discuss the current translational challenges of PSC-CM and their future perspectives for successful cardiac regenerative therapy.

Cell-based therapy
Cardiomyocytes are terminally differentiated cells that lack regeneration potential, thereby limiting their ability to restore the cardiac function after serious injury [7, 8]. In order to repair the myocardium, the most promising approach is to remuscularize the damaged tissue by replacing the lost cardiomyocytes, which could be done by transplantation of cells that are capable of cardiomyogenesis. Consequently, the search for the most suitable cell type for transplantation is therefore doubtlessly a crucial task. Table 1 summarized the cell types used for cardiac therapy and regeneration in pre-clinical and clinical studies.

Adult stem cells
Adult stem cells would probably be the first option that comes into one's mind, owing to their ability to develop into all cell types of the organ from which they originate and steer clear of the controversial ethical issue that has been haunting the use of embryonic stem cells. Skeletal myoblast, a precursor to adult skeletal myocyte, was the first cell type experimented for cardiac regeneration. Skeletal myoblasts were reported to regenerate functional skeletal muscle in response to injury [24, 25]. Owing to the ease of isolation, rapid in vitro expansion, and resistance to ischemia, they have been viewed as a potential candidate to remuscularize the injured heart [26]. Although most of the pre-clinical animal studies [27–32] and clinical studies [33, 34] of skeletal myoblasts have yielded promising results, many of the clinical trials were performed in conjunction with CABG or left ventricular assist device (LVAD) [35, 36], raising the ambiguity of the significant role of skeletal myoblasts in the therapy of heart failure. On the other hand, the therapeutic effects of transplanted BM-MNC in infarcted myocardium showed conflicting outcomes in animal studies. BM-MNC transplanted in a rat model [37] induced angiogenesis at the scar region and improved...
myocardial function, but no improvement in left ventricle function was observed in sheep [38] and porcine [39] models. The use of bone marrow-derived progenitor cells, such as HSC and EPC have also been studied in patients with both ischemic [40] and non-ischemic [41, 42] cardiomyopathies. The initial clinical results were encouraging but were disputable due to the small sample size. It is therefore unlikely to draw a definitive conclusion on the role of these cells in cardiac repair.

Of all the adult stem cell types, MSCs are in the center of attention for regenerative medicine. These multipotent stem cells were found to be readily available from various tissues and organs [43–48]. Studies have shown that MSCs are able to differentiate into several cell types [49–53] including functional cardiomyocytes in vitro [54, 55] and in vivo [56]. The emerging evidence on the homing potential of MSCs to the site of injury [57–59], coupled with their immunomodulatory properties, has made them more attractive for cardiac tissue repair. Several animal studies have reported the efficient engraftment and evidence of cardiomyogenesis of transplanted MSC at the host injury sites in myocardial infarction (MI) model [60, 61]. For instance, Quevedo et al. demonstrated that in the porcine model, injection of allogeneic male MSCs differentiated into myocyte, vascular muscle, and endothelial cells that integrated into female host myocardium. This was evident by the co-localization of the Y-chromosome with the trilineage markers [62]. Importantly, improvement in cardiac functions after MSC transplantation, as evidenced by the increased left ventricular ejection fraction (LVEF), myocardial blood flow (MBF), and contractility around the infarct border zone, was shown in the study. While extensive clinical trials that exploit MSC to repair the damaged myocardium are currently being conducted, both autologous and allogeneic MSC were generally reported to be safe and effective, except for one trial which showed no beneficial effect when MSCs were delivered through intravenous (IV) injection [63].

### Pluripotent stem cell-derived cardiomyocytes

**Human ES-derived cardiomyocytes**

Unlike adult stem cells, PSCs are highly expandable and can virtually differentiate into any adult somatic cell types, providing an unlimited source of cardiomyocytes. Numerous differentiation techniques have been developed to induce CMs from PSCs [64]. The initial differentiation method involved the embryoid body (EB) formation. EBs are spheroid aggregates that are able to differentiate into cells from all three germ layers within the three-dimensional structures [65]. Kehat and colleagues have demonstrated that human ESC-derived CMs can be isolated from spontaneously differentiated EB. However, this method has been reported to be

---

**Table 1** Summary of different cell types and animal models used in cardiac repair and regeneration

| Cell types           | Model                           | Outcome                                      | Mode of delivery                                      | References |
|----------------------|---------------------------------|----------------------------------------------|-------------------------------------------------------|------------|
| Pluripotent stem cells | Human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) | Improved cardiac function and neovascularization | Cell sheet transplantation at myocardium               | [9]        |
|                      | Pig                             | Increased ejection fraction and decreased myocardial wall stress | Cell sheet transplantation at epicardial               | [10]       |
|                      | Human embryonic stem cell-derived cardiomyocytes (hESC-CM) | Improved cardiac function                   | Injection in left ventricular wall                     | [11]       |
|                      | Pig                             | Improved cardiac function                   | Embryoid bodies transplantation at posterolateral wall of the left ventricle | [12]       |
| Adult stem cells     | Non-human primates              | Remuscularization of infarcted zone          | Intramyocardial injection                              | [13]       |
|                      | Mouse                           | Improved cardiac function                   | Injected beneath the coronary artery ligation         | [14]       |
|                      | Human embryonic stem cell-derived cardiovascular progenitors | Most patients were symptomatically improved with an increased systolic motion of the cell-treated segments | Sub-epicardial injection of cells in a fibrin patch   | [15]       |
|                      | Bone marrow-derived mononuclear cells (BM-MNC) and progenitor cells | Improved LVEF                                  | Intracoronary infusion                                | [16–18]    |
|                      | Human                           | No improvement of LVEF                      |                                                      | [19]       |
|                      | Bone marrow-derived mesenchymal stem cells (BM-MSC) | Reduced infarct size and scar formation | Transendocardial injection                            | [20, 21] |
|                      | Human                           | Improved LVEF                                | Epicardial placement of a MSC-sheet                   | [22]       |
|                      | Rat                             | Improved LVEF                                | Sub-epicardial injection                              | [23]       |

---

Liew et al. Stem Cell Research & Therapy (2020) 11:138  Page 3 of 15
inefficient and labor-intensive as only approximately 10% of the EBs exhibited spontaneous contractile characteristics and limited amount of CMs could be isolated by mechanical dissection from the beating areas [66]. As such, this EB-based method has then been supplanted by more refined methods that employ defined signaling factors and small molecules to manipulate nodal/activin, BMP4 [67, 68], and Wnt signaling [69, 70], which in turn promote cardiomyocyte mesodermal specification.

The feasibility and therapeutic efficacy of hPSC-CMs for cardiac repair after myocardial injury were tested on various animal models. Of note, one encouraging study revealed that the implanted hESC-derived CMs in slow heart-rate guinea pig model facilitated the repair of the infarcted heart and were able to achieve electrical integration with host myocardium [71]. Contradictorily, other researchers reported no significant improvement in cardiac function and limited electrical integration in chronic MI animal models following transplantation [72, 73]. Regardless of these mixed outcomes from the studies, the genuine therapeutic or side effect could be missed or overlooked as there are explicit differences between animal models and human. In order to achieve more precise evaluation of the therapeutic outcome and safety of using PSC-derived CMs in treating cardiac injury, a model with an electrical conduction system that closely resembles that of a human heart is therefore desirable. Accordingly, non-human primate models have been brought into play in various pre-clinical studies. Demonstrated by Chong et al., intramyocardial injection of hESC-CMs improved remuscularization of the infarcted heart in monkeys after ischemic reperfusion (I/R) injury, but complications associated with transient arrhythmia (abnormal heart rhythm) was observed in the study [13]. Another non-human primate MI model study, on the other hand, showed that transplanted human ESC-CMs improved LVEF, with only a subset of the animals experienced graft-associated arrhythmias [74]. The discrepancy in the risk of cardiac arrhythmias in the aforementioned studies was likely attributable to the difference in the disease model (I/R vs. MI), timing of cell delivery, the type, and dose of cardiomyocyte transplanted.

**iPSC-derived cardiomyocyte**

Since ESCs are derived from the inner cell mass of the blastocyst, its usage in research is therefore ethically controversial [75]. The discovery of induced pluripotent stem cell (iPSC) technology, a method of reprogramming somatic cells into pluripotent state using a cocktail of transcription factors, greatly opened up the new dimension of personalized medicine [76], as the use of patient-specific iPSCs to generate autologous grafts could circumvent the possible immune rejection and the ethical issue raised in human ESC. Accumulating evidence has shown that iPSCs display similar characteristics (surface markers, morphology, and growth properties) to that of ESCs [77, 78]. This has spurred interest in investigating the cardiogenic potential of iPSCs [79, 80]. Indeed, iPSC-derived CMs exhibit functional properties of cardiac cells, such as spontaneous beating, contractility, and ion channel expression, suggesting that they can be regarded as a substitution to CMs derived from ESCs in restoring the damaged myocardium [81]. Kawamura et al. have reported that transplantation of hiPSC-derived cardiomyocytes significantly improved LVEF and attenuated left ventricular remodeling in porcine MI model [82]. Whilst tremendous progress has been made in this field, the expectations of iPSC- and ESC-derived CMs have not been met and are yet to be ready for the application of cell therapy in heart failure.

**Translational challenges of PSC-CM in cell-based therapy**

**Immature phenotype**

Despite the remarkable improvement in developing well-defined differentiation protocols to generate PSC-CM, the maturation status of these cells differs tremendously from that of the adult CMs. Of note, PSC-CMs display immature phenotypes that closely resemble fetal CMs. In terms of morphology, hPSC-CMs appeared to be round and mononucleated, in contrast to adult cardiomyocytes that were binucleated and rod-like in shape [83–85]. In addition, the contractile unit of sarcomeres in hPSC-CMs is shorter and less organized as compared to their mature counterpart. The immaturity of hPSC-CM was also reflected by the absence of transverse tubules (T-tubules) [86, 87], inefficient contractility, difference in metabolism, and electrophysiological properties [88].

On top of the potential risk of arrhythmias upon transplantation, the lack of functional maturation in hPSC-CMs (as described in Table 2) results in inaccurate recapitulation of electrophysiological responses, thereby impeding its translation into clinical application.

With regard to this, many approaches that aim to enhance the maturation of hPSC-CMs in vitro have been sought and developed [106–109]. Prolonged culture [110], electrical stimulation [111–113], metabolic hormone [114–116], and ascorbic acid (AA) treatments [117] have been shown to induce a more mature phenotype of CMs with more organized sarcomere, improved contractile properties, and a shift in metabolism from anaerobic glycolysis towards oxidative phosphorylation [118]. Strategies including three-dimensional (3D) culture system that co-culture non-CMs and extracellular matrix (ECM) components [108], mechanical force imposed by cyclic stretch [119, 120], as well as microRNAs such as let-7 family, miR-499 and miR-1 [121, 122], were
also employed to enhance the maturation process. Despite the emergence of these improved maturation protocols, a standard method to accurately evaluate the level of the maturation of PSC-derived CMs is yet to be defined. Recently, a group of researchers had identified a set of genes with identical relative expression orderings (REOs) within adult cardiac tissue but reversely identical in ESCs [123]. The authors utilized this list of genes to calculate the maturity score and measured the tendency of PSC-CM maturation by comparing the score to that of adult cardiomyocytes. Using this scoring system, they found that the maturity scores of PSC-CMs from 4 different culture methods were on the rise with the extension of culture time (up to 120 days) but were still not reaching the score of adult CM (0.7638 vs 0.9997), suggesting that there is still a gap between mature-like PSC-CMs and adult cardiomyocytes in the heart.

Diverse cardiomyocyte subtypes (atrial, ventricular, and pacemaker cells)

On top of the variable maturation status in hPSC-CMs, currently available differentiation protocols also generated heterogeneous cell populations that contained atrial, ventricular, and pacemaker cells [124–126]. Many have disregarded the importance of purifying specific cardiac subtypes for subsequent clinical testing, but transplantation of a heterogeneous pool of CM into an infarcted heart might affect the therapeutic outcomes. A detailed review reported that atrial, ventricular, and pacemaker cells possess different cardiac action potential (AP) due to the different roles they play in maintaining cardiac function [127]. The maximal upstroke velocity (Vmax) of ventricular cells is the highest (200–300 V/s), followed by atrial cells (200 V/s) and pacemaker cells (4–5 V/s). Another feature to distinguish different cardiac subtypes is the presence of spontaneous depolarization during phase 4 of the AP in nodal cells. This spontaneous activity is extremely low in atrial cells and is completely absent in ventricular cells [127]. Hence, transplanting multiple subtypes of cardiac cells into the injured heart might lead to arrhythmias as they may not synchronize with the cardiac contractility in the host tissues.

In order to effectively treat the diseases that affect the specific regions of the heart, for example, to remuscularize the ventricular wall of the patient suffering from MI, the ideal approach would be to transplant the population of cells exclusively comprised of ventricular cardiomyocytes. Thus, various sorting and enrichment methods were developed to purify the chamber-specific cardiomyocytes from in vitro differentiated hPSC-CM. Zhang et al. (2011) demonstrated that the addition of retinoic acid (RA) to RALDH2+ mesoderm at the early stage of differentiation induced atrial-like cardiomyocytes at the expense of ventricular cells [128]. Contrarily, inhibition of canonical Wnt pathway by treatment with IWR-1 induced high yield of ventricular cardiomyocytes from hESC-derived cardiovascular progenitor cells [129]. Even with these improvements in chamber-specific cell purification, we are still far from generating a pure population of desired cardiac cell subtypes.

On the other hand, a stable transgenic hPSC line harboring fluorescent reporter under the transcriptional control of human myosin light chain-2V promoter (MLC2V) [130–132] and chick ovalbumin upstream promoter transcription factor II (COUP-TFII) [133] were developed to isolate ventricular and atrial cardiomyocytes, respectively. Despite the robust and high efficiency in enriching specific subtypes after cardiac differentiation of PSCs, the use of virus-based vector, again, has raised safety issues including immunogenicity and insertional mutagenesis risk that hinder their application in future clinical treatment. Among the handful publications about cell-type enrichment, none of the studies

| Characteristics | PSC-CM | Adult CM | References |
|-----------------|--------|----------|------------|
| Morphology      | Cell shape | Circular | Rod-shaped | [89–91] |
|                 | Nucleation | Single nucleated | 25–30% binucleated | [92, 93] |
|                 | Mitochondrial content | Slender and long, lesser than in adult CM | Elongated shape, 35% of total cell volume | [94, 95] |
|                 | Surface area | 1000-1300 μm² | 10,000-14,000 μm² | [96, 97] |
| Metabolism      | Substrate preference | Glucose | Fatty acid | [98, 99] |
| Sarcomere       | Myofibrillar isoform switch (myosin heavy chain) | β = α | β > α | [100–102] |
|                 | Myofibril | Low density | High density | [83, 91, 103] |
|                 | Alignment | Random | Anisotropic | [91, 104] |
| Electrophysiological properties | Upstroke velocity | Slower | Faster | [83, 97] |
|                 | Contraction | Asynchronous | Synchronous | [98, 105] |
reported whether these cells bear resemblance to the right or left chambers of the heart. This could in turn represent another hitch as it was previously reported that the left and right ventricular cardiomyocytes are physiologically different and therefore might affect the outcome of cell therapy [134–136]. For example, owing to their responsibility to pump oxygenated blood to all parts of the body, left ventricular cardiomyocytes are particularly desired in the case of treating MI.

Low engraftment rate of transplanted cells
The poor survival and engraftment rate of transplanted cells are some of the major unresolved problems that constrain the efficacy of stem cell therapy in treating human diseases. This is due to the fact that transplanted cells are not capable of withstanding the ischemic environment at the site of the injury and the subsequent triggered immune response. Apart from that, the route of administration also affects the engraftment efficiency of hPSC-CM in the heart. Cells can be delivered to the injured myocardium through intramyocardial (IM), intracoronary (IC), or intravenous (IV) injections. Direct IM injection is the most common route of cell administration, but a substantial amount of cell leakage from the punctured holes after injection was reported. Besides, IM, performed through open-chest surgery, is also subjected to high-wall shear stress and acute inflammation [137]. In contrast, injection of cells into the coronary artery or the cardiac vein (IC injection) are mechanical less stressful than IM injection and showed minimal risk of injection-induced ventricular arrhythmias [138]. IV injection, on the other hand, appeared to be the least invasive mode of delivery but with extremely low cell retention as most of the transplanted cells were lost during their travel in the bloodstream and ended up being trapped in the lung, kidney, liver, and other organs [139–141]. Regardless of the route of delivery, engraftment of the transplanted cells to the infarcted myocardium is rare (< 2%) [142, 143].

Several strategies to improve cell survival and engraftment are currently under investigation. In line with the advancement of biomaterial technology, hydrogel has emerged as one of the promising candidates for cardiac tissue engineering. This hydrophilic polymer could provide 3D structural support to the transplanted cell and enhance cell retention in the injured myocardium [144–146]. Using a rat acute MI model, Christman et al. validated the effect of fibrin gel in improving the survival of transplanted cells and consequently the cardiac function. The infarct scar size of the rat injected with myoblast-embedded in fibrin was significantly decreased after 5 weeks post transplantation as compared to the control group (myoblasts embedded with bovine serum albumin). Additionally, the use of fibrin promoted angiogenesis and arteriogenesis in the ischemic myocardium [145]. Other biomaterials, both natural (e.g., collagen, alginate) and synthetic (e.g., peptide nanofibers) were also shown to increase cell survival and stimulate tissue regeneration [147–149].

More recently, tissue engineering technology has also been widely explored for its applicability in cell-based tissue regeneration therapy. The creation of scaffold-free cell sheets, 3D-printed cardiac tissue with extracellular matrix (ECM) and human engineered heart tissue (hEHT), which can be implanted directly to the damaged myocardium has shed light in offering potential solution to the low cell viability and engraftment seen in cell suspension delivery methods [150, 151]. Cell sheet is engineered by culturing the cells on a thermo-responsive polymer surface in monolayer or stacked into multilayers in order to preserved cell-to-cell connection and fabricated 3D cardiac tissues, followed by implantation into the damaged tissue. Transplantation of hiPSC-CM sheets at the myocardial infarct region in a porcine model of ischemic cardiomyopathy improved cardiac performance by structural and electromechanical integration into the host myocardium [82]. Another successful example of cell sheet technology in cardiac regeneration was demonstrated by Sekine et al., in which the author reported that cell sheet transplantation yielded greater cell survival over cell injection, with significant improvement in cardiac function and increased vascularization at the infarcted zone [152]. Using a multiphoton-excited 3D printing technology, hiPSC-derived cardiac muscle patch (hCMP) consisting of hiPSC-CM and other cardiac cell types (hiPSC-EC and hiPCS-SMC) was also generated and evaluated in a mouse MI model. The animals showed improved cardiac functions, reduced infarct expansion, increased vascular density, and cell proliferation [153]. Additionally, transplanted hEHT derived from iPSC-CMs and human endothelial cells (hEC) also resulted in remuscularization of the scar heart tissue and promoted cardiac contractile function of guinea pig model [154]. While moderate success of engineered cardiac-like tissue has been achieved in myocardial repair of animal models, several problems arise. These include (i) short survival period of the transplanted tissue, (ii) ineffective integration to the host tissue resulting from insufficient vascularization, (iii) the need for open-chest surgery, (iv) risk of arrhythmia associated with large graft size, and (v) biodegradability of biomaterials used, all of which collectively hamper the success in clinical application.

Teratoma formation and immune rejection
Other concerns related to the clinical application of hPSC-derived cells include the risk of teratoma formation and immune rejection following transplantation.
The presence of the residual undifferentiated hPSCs, resulting from inefficient differentiation of hPSCs and subsequent poor purification of terminally differentiated cell types, will potentially lead to tumorigenesis. Presently, there is no evidence of teratoma formation after transplantation of hPSC-derived CM into animal models [13, 71, 73, 155–157]. However, more in-depth studies that involve non-primate human models, generation of highly purified mature cardiomyocytes, and long-term follow-up post transplantation are certainly necessary to reassess the safety and efficacy of PSC-derived cell therapy. Moreover, karyotype instability caused by prolonged in vitro culture of PSCs remains a concern for potential neoplastic transformation [158, 159].

Given that most of the PSCs studies employed immunodeficient or immunosuppressed animals [13, 68, 71, 160], the possibility of PSC-based therapies in provoking unwanted immune reaction in clinical testing should not be disregarded. Whilst immunosuppressive therapy post transplantation could improve graft survival rate, undesirable complications such as increased risks associated with infection and malignancy are yet to be resolved [161]. Alternatively, the establishment of diverse human leukocyte antigen (HLA) typed PSC line has also been suggested to expand the number of target patients that can benefit from PSC-based cardiac therapy [162, 163].

**Alternative strategies for successful cardiac regeneration**

The concept of cardiac regeneration clings to the idea of repairing and/or replacing damaged cardiomyocytes. It was initially thought that the physical close proximity of PSC-CMs and their subsequent engraftment into the host tissue contributed to the functional recovery of MI in animal models. However, it has recently been suggested that the therapeutic efficacy of these transplanted cells could be executed by paracrine effects. This hypothesis stemmed from the findings that showed functional restoration of the injured murine myocardium despite suboptimal cell engraftment. Furthermore, the observation of abundant secretion of cardio-protective factors involved in anti-apoptotic, pro-angiogenic, pro-cell proliferation, and migration from PSC-CM to the host myocardium implied that the paracrine effects, rather than cell incorporation, could be accountable for the significant therapeutic impact seen in the in vivo studies [164, 165]. Hence, this points towards the development of cell-free therapy that aims to stimulate the endogenous mechanism of regeneration in the heart (Fig. 1). Several innovative strategies have been proposed: (i) administration of cardio-protective growth factors, (ii) overexpression of therapeutic proteins using modified RNA (modRNA), and (iii) delivery of extracellular vesicles harboring cardiac-regenerative biomolecules. A summary of these strategies are provided in Table 3.

**Growth factors**

Direct injection of cardiac-protective growth factors into the infarcted heart is the most straightforward way that offers immediate therapeutic effect and allows control over the administered dose. Therapeutic angiogenesis has been viewed as an effective approach in managing the disease as it could induce neovascularization that improves blood supply at the infarcted tissue. In line with this, most of the pre-clinical studies involving growth factor therapy for heart repair focused on vascular endothelial growth factor-A (VEGF) [184–187] and fibroblast growth factor (FGF) [188–190]. Porcine model of chronic myocardial ischemia treated with VEGF, either by IC delivery or direct epicardial implantation, showed significant improvement in the coronary flow [176]. Suppression of cardiomyocyte apoptosis is another strategy to alleviate ischemic injury in the cardiac tissue. Treatment with hepatocyte growth factor (HGF), an anti-apoptotic factor, reduced apoptosis of cardiomyocytes and lesion size in rats [180]. Other anti-apoptotic factors such as platelet-derived growth factor (PDGF) [181] and interleukin (IL) [182, 183] have also been examined for their therapeutic potential in endogenous cardiac repair. Other potential alternatives to these approaches include induction of CM proliferation with acidic fibroblast growth factor (FGF-1) [177], neuregulin (NRG-1) [178], and peristin [179]. The aforementioned growth factors have demonstrated the safety and therapeutic efficacy in treating ischemic heart disease (IHD), particularly MI [191, 192]. However, the issues of short biological half-life, low specificity, and the need of repetitive injection to sustain therapeutic efficacy hamper its progress into clinical application.

**Modified mRNA**

On the other hand, endogenous cardiac repair can be achieved through the administration of messenger RNA (mRNA) encoding the protein of interest. Direct transfection of mRNA to the target cells enhances the translation of the desired therapeutic protein, but held back by low stability of mRNA and possible activation of the immune response. Several groups have shown that structural modification of RNA through the incorporation of 5-methylcytidine (5mC), pseudouridine (Ψ), 5-methyluridine (5mU), or N6-methyladenosine repressed Toll-like receptor (TLR) activation, thereby avoid triggering unwanted cellular immune response [193, 194]. Robust but transient expression of the encoded protein induced by modRNA could eradicate the risk of malignancy that would probably be caused by the prolonged expression of the delivered therapeutic molecules, a side
effect sometimes seen in conventional gene therapy [195]. A recent noteworthy study revealed that modRNA encoding human VEGF-A injected into the mice infarcted heart resulted in reduced infarct size, ameliorated myocardial perfusion, and improved survival [172]. Importantly, the authors uncovered the underlying mechanism, in which VEGF-A modRNA stimulated the proliferation of epicardial progenitors, followed by its migration to the injured myocardium and subsequent differentiation towards cardiovascular lineage. More recently, modRNAs encoding for IGF1, EGF, HGF, TGFb1, TGFb2, SDF-1, FGF-1, GH, and SCF have been widely investigated in cardiac cells and tissue [172, 174, 175, 196–198]. While most of these modRNAs showed certain level of therapeutic effects, more studies that aim to enhance transfection efficiency of the modRNA and the subsequent translation are fundamental in realizing their application in clinical therapy.

**Stem cell-derived exosomes as cell-free therapy in treating cardiovascular diseases**

The discovery of extracellular vesicle, in particular, exosome, as an important messenger in facilitating intercellular communication through transporting and transferring bioactive molecules (proteins and RNAs) between cells has opened a new perspective of applying cell-free therapy in cardiac regeneration [199]. Mouse ESC-derived exosomes have been shown to promote cardiac repair and preserve cardiac function in mouse MI model [200, 201]. In order to enhance the therapeutic effect of exosome in restoring the damaged heart, PSCs could also be genetically modified to secrete exosomes that are enriched with cardioprotective miRNAs, such as miR-21 and miR-210 [202–205]. Indeed, the proof-of-concept of exosome in delivering small RNA molecules to the targeted tissue has recently been confirmed by Alvarez-Erviti et al. [206]. More details about the role of exosome in cardiac regeneration were previously reviewed by Ma et al. [207]. Whilst PSC-derived exosomes offer an innovative approach in stimulating endogenous heart repair, the exact content in exosomes remains elusive. Such unidentified endogenous biomolecules in the exosomes might be transported to the recipient cells and lead to unknown side effects. An in-depth and rigorous characterization of its contents is therefore essential to ensure the safety of applying exosomes in cell-free therapy.

### Table 3 Summary of cell-free approaches used in cardiac repair

| Alternative strategies | Model | Outcome | Type of disease | References |
|-----------------------|-------|---------|-----------------|------------|
| Exosomes              | hESC-derived MSCs | Mouse | Reduced infarct size | Myocardial infarction/reperfusion injury | [166–168] |
|                       | hESCSC-derived cardiovascular progenitor | Mouse | Reduced left ventricular end-systolic and end-diastolic volumes | Chronic heart failure | [169] |
|                       | hiPSC-derived cardiovascular progenitor | Mouse | Improved cardiac function through decreased left ventricular volumes and increased LVEF | Myocardial infarction | [170] |
|                       | MSCs | Rat | Reduced apoptosis and the myocardial infarct size | Reperfusion injury | [171] |
| Modified mRNA          | Vascular endothelial growth factor (VEGF)-A | Mouse | Induced vascular regeneration | Myocardial infarction | [172] |
|                       | Insulin-like growth factors (IGFs) | Mouse | Promote cardiomyocyte survival and abrogate cell apoptosis post-MI | | [175] |
| Growth factors        | VEGF | Pig | Increased myocardial blood flow and improved regional ventricular function | Chronic myocardial ischemia | [176] |
|                       | Fibroblast growth factors (FGFs) | Mouse | Induced cardiomyocyte proliferation and division | Ischemic heart disease | [177] |
|                       | Neuregulin 1 (NRG-1) | Mouse | Induced cardiomyocyte proliferation and promotes myocardial regeneration | Myocardial infarction | [178] |
|                       | Periostin | Rat | Reduced fibrosis and infarct size, and increase angiogenesis | Myocardial infarction | [179] |
|                       | Hepatocyte growth factor (HGF) | Rat | Reduced apoptosis of cardiomyocytes and lesion size | Reperfusion injury | [180] |
|                       | Platelet-derived growth factor (PDGF) | Rat | Decreased infarct size, decreased cardiomyocyte death, and preserved systolic function | Ischemia/reperfusion/myocardial infarction | [181] |
|                       | Interleukin (e.g., IL-33, IL-11) | Rat | Reduced cardiomyocyte apoptosis, decreased infarct size and fibrosis, and improved ventricular function | Ischemia/reperfusion | [182] |

Liew et al. Stem Cell Research & Therapy (2020) 11:138

Page 8 of 15
Conclusion

The therapeutic potential of PSC-derived CM in cell-based therapy in terms of regenerating the damaged heart is evident by various successes in animal models. However, this seemingly promising therapeutic outcomes of PSC-derived CMs should not have overshadowed the unaddressed issues, particularly the immature phenotype and diverse cardiac cell subtypes that were generated during the differentiation from PSCs. Although many studies have been performed to develop defined differentiation and purification protocols for CMs, it is still unclear to which extent the maturation of PSC-CMs would be ideal for optimal results. Other clinical hurdles, such as tumorigenicity, immunogenicity, and risk of arrhythmias, still remain to be resolved. We are well informed with the favorable and unfavorable impacts of PSC-CMs in animal models, but we know incredibly little about its implication in human. Further studies using humanized animal models are crucial in order to ensure precise prediction of human physiological responses and safety in clinical application. In addition, large-scale production of clinically compliant PSC-CMs is also required for translation into therapeutic reality. As such, stem cell-derived exosome that could possibly regenerate the damaged heart without the involvement of cells appears to be a potential approach to overcome the aforementioned problems of cell-based therapy. To achieve maximal therapeutic outcomes, factors (summarized in Table 4) may be considered in order to generate combinatorial therapies customizable to the severity and the types of heart disease. For instance, PSC-derived cardiac patch would be useful in replacing a large region of ventricular scar, whereas endogenous cardiac regeneration induced by MSC-derived exosome cargo with cardio-protective factors could prevent disease progression.

Table 4 Comparison between cell-based and cell-free approaches for cardiac repair and regeneration

|                | Cell-based therapy                                                                 | Cell-free therapy                                                                 |
|----------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| **Origin**     | Accessible in various organs and tissues                                           | Cell source dependent                                                             |
| **Ethical issues** | No                                                                                 | Yes                                                                               |
| **Genetics stability** | Genetically stable                                                                  | Genetically unstable                                                              |
| **Safety**     | No evidence for tumorigenesis                                                      | Possible tumorigenic risk                                                         |
| **Immunogenicity** | Low risk of immune rejection                                                       | Possible risk of immune rejection                                                   |
| **Risk of arrhythmia** | Low risk of arrhythmia                                                               | Possible risk of arrhythmia                                                       |
| **Factors determining therapeutic efficacy** | Highly dependent on the state of maturation, cell number, and viability during transplantation | Loading dosage                                                                   |
| **Approach-related limitations** | Large number of cells are required for significant therapeutic effect               | Short biological half-life and low specificity                                      |

**Abbreviations**

PSC-CM: Pluripotent stem cell-derived cardiomyocytes; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; BM-MNC: Bone marrow mononuclear cells; HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; MSC: Mesenchymal stem cells; LVAD: Left ventricular assist device; LVEF: Left ventricular ejection fraction; MBF: Myocardial blood flow; IV: Intravenous injection; EB: Embryoid body; IR: Ischemia reperfusion; iPSCs: Induced pluripotent stem cells; AA: Ascorbic acid; ECM: Extracellular matrix; REOs: Relative expression orderings; AP: Action potential; Vmax: Maximal upstroke velocity; RA: Retinoic acid; Mi: Myocardiac infarction; ML2C2V: Myosin light chain-2V promoter; COUP-TFII: Chick ovalbumin upstream promoter transcription factor II; M: Intramyocardial; IC: Intracoronary; hEHT: Human engineered heart tissue; hCMP: hiPSC-derived cardiac muscle patch; MLA: Human leukocyte antigen; modRNAs: Modified RNA; VEGF: Vascular endothelial growth factor-A; FGF: Fibroblast growth factor; HGF: Hepatocyte growth factor; PDGF: Platelet-derived growth factor; IL: Interleukin; FGF-1: Fibroblast growth factor; NRG-1: Neuregulin; IHD: Ischemic heart diseases; mRNA: Messenger RNA; SmC: 5-Methylcytidine; Ψ: Pseudouridine; SmU: 5-Methyluridine; TLRs: Toll-like receptors

**Acknowledgements**

Publication fees were covered by the Institute of Molecular and Cell Biology, A*STAR.
Authors’ contributions
Liew L.C., Ho B.X., and Soh B.S. wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work is supported by the Agency for Science, Technology and Research (Singapore) and by a grant from the National Medical Research Council to B.S.S (NMRC/OFYIRG/0017/2016). Beatrice Xuan Ho is supported by the National University of Singapore graduate scholarship.

Availability of data and materials
Not applicable

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Disease Modeling and Therapeutics Laboratory, A*STAR Institute of Molecular and Cell Biology, 61 Biopolis Drive Proteos, Singapore 138673, Singapore. 2Department of Biological Sciences, National University of Singapore, Singapore 117543, Singapore. 3Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.

Received: 6 February 2020 Revised: 2 March 2020 Accepted: 10 March 2020 Published online: 26 March 2020

References
1. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.
2. Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circ Res. 2002; 90(10):1044–54.
3. Haqqani HW, Mond HG. The implantable cardioverter-defibrillator lead: principles, progress, and promises. Pacing Clin Electrophysiol. 2009;32(10): 1336–53.
4. Alba AC, Delgado DH. The future is here: ventricular assist devices for the failing heart. Expert Rev Cardiovasc Ther. 2009;7(9):1067–77.
5. Braunwald E. Cell-based therapy in cardiac regeneration: an overview. Circ Res. 2018;123(2):132–7.
6. Sun R, Li X, Liu M, Zeng Y, Chen S, Zhang P. Advances in stem cell therapy for cardiovascular disease (review). Int J Mol Med. 2016;38(1):23–9.
7. Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisen J, et al. Cardiomyocyte regeneration: a consensus statement. Circulation. 2017; 136(7):680–6.
8. Bergmann O, Zduńek S, Felder A, Salpekar M, Alkass K, Bernard S, et al. Dynamics of cell generation and turnover in the human heart. Cell. 2015; 161(7):1566–75.
9. Masumoto H, Ikino T, Takeda M, Fukushima H, Marui A, Katayama S, et al. Human iPSC cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014;4:6716.
10. Ishida M, Miyagawa S, Saito A, Fukushima S, Harada A, Ito E, et al. Transplantation of human-induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction. Transplantation. 2019;103(2):291–8.
11. Lafllamme MA, Gold J, Xu C, Hassanpour M, Rosler E, Police S, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005;167(4):653–71.
12. Kehat I, Klimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004;22(10):1282–9.
13. Chong JJ, Yang X, Don CW, Minami E, Liu YW, Weyers JJ, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273–7.
14. Yu Y, Qin N, Lu XA, Li J, Han X, Ni X, et al. Human embryonic stem cell-derived cardiomyocyte therapy in mouse permanent ischemia and ischemia-reperfusion models. Stem Cell Res Ther. 2019;10(1):167.
15. Menasché P, Vanneaux V, Hagege A, Bel A, Cholley B, Parouchev A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol. 2018;71(4):429–38.
16. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009–17.
17. Strauer BE, Brehm M, Zeus T, Korting M, Hernandez A, Soirg RV, et al. Repair of injured myocardium by autologous intacoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106(19):1913–8.
18. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schachinger V, Lehmann R, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011;100(10): 925–34.
19. Soder D, Manka R, Mocettini T, Lo Cicero V, Emmert MY, Kleisy C, et al. Effect of bone marrow-derived mononuclear cell treatment, early or late after acute myocardial infarction: twelve months CMR and long-term clinical results. Circ Res. 2016;119(3):481–90.
20. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncan YV, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79.
21. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):623–73.
22. Tano N, Naita T, Kanelo M, Ikbe C, Coppen SR, Campbell NG, et al. Epicardial placement of mesenchymal stromal cell sheets for the treatment of ischemic cardiomyopathy: in vivo proof-of-concept study. Mol Ther. 2014; 22(10):1864–71.
23. Herreross J, Prosper F, Perez A, Gavira JJ, Garcia-Yellos M, Barja J, et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J. 2003;24(22):2120–22.
24. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961;9:493–5.
25. Buckingham M, Montarras D. Skeletal muscle stem cells. Curr Opin Genet Dev. 2008;18(4):330–6.
26. Chachques JC, Acar C, Herreross J, Trainini JC, Prosper F, D’Attellini N, et al. Cellular cardiomyoplasty: clinical application. Ann Thorac Surg. 2004;77(3):121–31.
27. Taylor DA, Atkins BZ, Hunspreugue P, Jones TR, Reedy MC, Hutcheson KA, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4(8):929–33.
28. He KL, Yi GH, Sherman W, Zhou H, Zhang GP, Gu A, et al. Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs. J Heart Lung Transplant. 2005;24(11):1940–9.
29. Fukushima S, Coppen SR, Lee J, Yamahara K, Felkin LE, Terracciano CM, et al. Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat. PLoS One. 2008;3(8): e3071.
30. Farahmand P, Lai TY, Weisel RD, Fazel S, Yau T, Menasché P, et al. Skeletal myoblasts preserve remote matrix architecture and global function when implanted early or late after coronary ligation into infarcted or remote myocardium. Circulation. 2008;118(14 Suppl):S130–7.
31. Gavira JJ, Perez-Izlarbe M, Abizanda G, Garcia-Rodriguez A, Orbe J, Paramo JA, et al. A comparison between percutaneous and surgical transplantation of autologous skeletal myoblasts in a swine model of chronic myocardial infarction. Cardiovasc Res. 2006;71(4):744–53.
32. Chachques JC, Duarte F, Cattadori B, Shafy A, Lila N, Chatellier G, et al. Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study. J Thorac Cardiovasc Surg. 2004;128(2): 245–53.
33. Menasché P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, et al. Myoblast transplantation for heart failure. Lancet. 2001;357(9252):279–80.
34. Menasché P, Hagege AA, Vilquin JT, Desnos M, Abeggel E, Pouzet B, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41(7):1078–83.

35. Gavira JJ, Herreros J, Perez A, García-Velloso MJ, Barba J, Martín-Herrero F, et al. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg. 2006;131(4):799–804.

36. Dib N, Michler RE, Pogani FD, Wright S, Kereiakes DJ, Lengerich R, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112(12):1748–55.

37. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100(19 Suppl II):S247–56.

38. Bel A, Messas E, Agbulut O, Richard P, Samuel JL, Bruneval P, et al. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation. 2003;108(Suppl II):S247–52.

39. Waksman R, Fournadjev J, Baffour P, Rakita R, Heilinga D, Leborgne L, et al. Transmucosal autologous bone marrow-derived mononuclear cell therapy in a porcine model of chronically infarcted myocardium. Cardiovasc Radiat Med. 2004;5(3):125–31.

40. Patel AN, Geffrin L, Vina RF, Salsavsky J, Urschel HC, Jr., Komos R, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg. 2005;130(8):1631–8.

41. Vrtovec B, Poglajen G, Sever M, Lezaic L, Domanovic D, Cernelc P, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail. 2011;17(4):272–81.

42. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domonavic D, Cernelc P, et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res. 2013;112(12):e165–73.

43. Zvářík NJ, Marinova-Mutafchieva L, Adams G, Edwards CI, Moss J, Burger JA, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2002;4(6):r77–88.

44. Romanov YA, Svintsitskaya VA, Smirnov VV. Searching for alternative sources of multipotent stem cells in human adipose tissue. Int J Dev Biol. 2004;48(3–4):193–9.

45. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human mesenchymal stem cell transplantation for cardiac ischemia.Curr Opin Biotechnol. 2004;15(3):266–71.

46. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac regeneration. Proc Natl Acad Sci U S A. 2006;103(32):12167–72.

47. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue ‘mesenchymal stem cells’ lack the capacity for long-term engraftment and differentiation. Tissue Eng. 2002;8(2):209–18.

48. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human mesenchymal stem cell transplantation for cardiac ischemia. J Card Fail. 2011;17(4):272–81.

49. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic cytokines and support long-term hematopoiesis when differentiated toward myogenic lineage. J Mol Cell Cardiol. 2007;41(12):1851–9.

50. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human mesenchymal stem cell transplantation for cardiac ischemia. J Card Fail. 2011;17(4):272–81.

51. Huang JI, Chien KR. Stem cell transplantation in the heart. Cell. 2006;124(6):753–6.

52. Zhang J, Ceurip M, Tkachuk E, Saavedra J, Vo B, et al. Human bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):911–20.

53. Kehat I, Kenyagin-Karsenti D, Snir M, Segov H, Arinit M, Geppstein A, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108(3):407–14.

54. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453(7194):524–8.

55. Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, Murry CE. Directed cardiomyocyte differentiation from human pluripotent stem cells by temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848–57.

56. Hatzistergos KE, Quevedo H, Osokuei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):911–20.

57. Quevedo HC, Hatzistergos KE, Osokuei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009;106(33):14022–7.

58. Mouiseddine M, Francois S, Semont A, Sache A, Allenet B, Kessler PD. Human mesenchymal stem cell differentiation to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(19):1933–8.

59. Hatzistergos KE, Quevedo H, Osokuei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):911–20.

60. Prakash VS, et al. Randomized, double-blind, phase I/II study of intravenous placenta-derived cells have mesenchymal stem cell potential. Stem Cells. 2004;22(5):649–58.

61. Hatzistergos KE, Quevedo H, Osokuei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):911–20.

62. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via microfabricated cell-repellent microwell arrays. Sci Rep. 2014;4:7402.

63. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via microfabricated cell-repellent microwell arrays. Sci Rep. 2014;4:7402.

64. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via microfabricated cell-repellent microwell arrays. Sci Rep. 2014;4:7402.

65. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via microfabricated cell-repellent microwell arrays. Sci Rep. 2014;4:7402.
77. Takahashi K, Tanabe K, Ohmukai M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.

78. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.

79. Mauritz C, Schwankie K, Reppel M, Neef S, Katsimtaki K, Maier LS, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008;118(5):S507–17.

80. Zhang J, Wilson GF, Soerens AG, Koonech CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104(4):e30–41.

81. Pfannkuche K, Liang H, Passier R, et al. The human adult cardiac myocyte phenotype. Cardiovasc Res. 2003;58(2):423–43.

82. Snir M, Kehat I, Gepstein A, Coleman R, Itskovitz-Eldor J, Livne E, et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol. 2003;285(6):H555–63.

83. Ziman AP, Gomez-Uzqueta NL, Bloch RJ, Lederer WJ. Excitation-contraction coupling changes during postnatal cardiac development. J Mol Cell Cardiol. 2010;48(2):379–86.

84. Bird SD, Doevendans P, Van Rooijen MA, Brutel de la Riviere A, Hassink R, et al. The early embryonic cardiac myocyte as a model for cardiac morphogenesis. Circulation. 2003;107(21):2733–40.

85. Mumme C, Smits J, Henningsen G, et al. Functional attributes of engineered heart tissues in vitro and their application in myocardial tissue engineering. Adv Drug Deliv Rev. 2012;64:1270–1300.

86. Machinj S, Greenway SC. Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes. World J Stem Cells. 2010;2:133–43.

87. Kim HD, Kim DJ, Lee JJ, Rah BJ, Sava Y, Schaper H. Human fetal heart development after mid-term: morphometry and ultrastructural study. J Mol Cell Cardiol. 1992;24(9):949–65.

88. Veerman CC, Kosmidis G, Mumme C, Caes K, Verheugt FW, et al. Immaturity of human cardiac stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? Stem Cells Dev. 2015;24(10):1035–52.

89. Ferri NT, Radics M. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues. Adv Drug Deliv Rev. 2016;96:110–34.

90. Olivetti G, Guglielmo A, Maestri R, Corradi D, Lagrasta C, Gambert SR, et al. Aging, cardiac hypertrophy and ischemic cardiomyopathy do not affect the proportion of mononucleated and multinucleated myocytes in the human heart. J Mol Cell Cardiol. 1996;26(7):1463–77.

91. Molla M, Benelli K, Walsh S, Savla J, Das LT, Park SY, et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci U S A. 2013;110(4):1446–51.

92. Garcia-Perez C, Hajnoczky G, Csordas G. Physical coupling supports the local regulation, cardiac ion channel expression and development of contractility. Front Physiol. 2013;4:102.

93. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Liew et al. Stem Cell Research & Therapy 2020:11:138.

94. Pacifici M, Park H, Shing H, Conci T, Schoen FJ, Langer R, et al. Functional maturation of human pluripotent stem cell derived cardiomyocytes in vitro–correlation between contraction force and electrophysiology. Biomaterials. 2015;51:138–30.

95. Keung W, Boheler KR, Li RA. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2014;5(1):17.

96. Lopaschuk GD, Jaszewski JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol. 2010;56(2):130–40.

97. Zhou J, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104(24):2923–31.

98. Sageh P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104(24):2923–31.

99. Siedner S, Kruger M, Schreier B, Metzler D, Rohe W, Fleischmann BK, et al. Developmental changes in cardiac fibroblasts of the early embryonic and the adult stage in the mouse heart. J Physiol. 2003;548(2):493–505.

100. Xu XQ, Soo SY, Sun W, Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells. 2009;27(9):2163–74.

101. Maitland M, van Berlo JH, Molinard JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. 2013;14(1):38–48.

102. Gerdes AM, Kellerman SE, Moore JA, Muffy KE, Clark LC, Reaves P, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992;86(2):426–30.

103. Liu B, Zhang D, Burac N. Functional cardiac tissue engineering. Regen Med. 2012;7(2):187–206.

104. Theron TJ, Rocha AM, Campbell KF, Ponce-Balbuena D, Willis BC, Guerrero-Serna G, et al. Extracellular matrix-mediated maturation of human pluripotent stem cell-derived cardiac monolayer structure and electrophysiological function. Circ Arrhythm Electrophysiol. 2016;9(4):e003638.

105. Ulmer BM, Steoer A, Schulze ML, Patel S, Gucek M, Mannhardt I, et al. Cardiac contractile work contributes to maturation of energy metabolism in hPSC-derived cardiomyocytes. Stem Cell Reports. 2018;10(3):834–47.

106. Chadrin IF, Allen BW, Qian Y, Jackman CP, Carlson AL, Juhasz ME, et al. Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat Commun. 2017;8(1):1825.

107. Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556(7700):239–43.

108. Lundy SD, Zhu WZ, Regnier M, Laffamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Dev. 2013;22(14):1991–2002.

109. Johnson TB, Kent RL, Bubolz BA, McDermott PJ. Electrical stimulation of cardiomyocytes: role of coculture with visceral endoderm-like cells. Br J Pharmacol. 2012;165(7):1705–17.

110. Johnson TB, Kent RL, Bubolz BA, McDermott PJ. Electrical stimulation of cardiomyocytes: role of coculture with visceral endoderm-like cells. Br J Pharmacol. 2012;165(7):1705–17.

111. Johnson TB, Kent RL, Bubolz BA, McDermott PJ. Electrical stimulation of cardiomyocytes: role of coculture with visceral endoderm-like cells. Br J Pharmacol. 2012;165(7):1705–17.

112. Johnson TB, Kent RL, Bubolz BA, McDermott PJ. Electrical stimulation of cardiomyocytes: role of coculture with visceral endoderm-like cells. Br J Pharmacol. 2012;165(7):1705–17.

113. Liau B, Zhang D, Burac N. Functional cardiac tissue engineering. Regen Med. 2012;7(2):187–206.

114. Liau B, Zhang D, Burac N. Functional cardiac tissue engineering. Regen Med. 2012;7(2):187–206.

115. Yang X, Rodriguez M, Pabon L, Fischer KA, Reinecke H, Regnier M, et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes–derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296–304.

116. Parikh SS, Blackwell DJ, Gomez-Hurtado N, Frisk M, Wang L, Kim K, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556(7700):239–43.

117. Cao N, Liu Z, Chen Z, Wang J, Chen T, Zhao X, et al. Ascorbic acid enhances functional cardiac tissue engineering. Regen Med. 2014;9(3):323–33.

118. Kerscher P, Bussie BS, DeSimone KM, Dunn DA, Lipke EA. Characterization of mitochondrial populations during stem cell differentiation. Methods Mol Biol. 2015;1264:453–63.
mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007;1(1):19–24.

161. Chinen J, Buckley RH. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S324–35.

162. Taylor CI, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 2005;366(9502):1929–25.

163. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells. 2007;25(4):983–5.

164. Tachibana A, Santoso MR, Mahmoudi M, Shukla P, Wang L, Bennett M, et al. Paracrine effects of the pluripotent stem cell-derived cardiac myocytes salvage the injured myocardium. Circ Res. 2017;121(6):e22–36.

165. Ong SG, Huber BC, Lee WH, Kodo K, Ebert AD, Ma Y, et al. Mesenchymal single-cell analysis of transplanted human induced pluripotent stem cell-derived cardiomyocytes after acute myocardial infarction. Circulation. 2015;132(8):762–71.

166. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10(3):301–12.

167. Liu L, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214–23.

168. Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, et al. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012;2012:971907.

169. Kervadec A, Bellamy V, El Harane N, Arslan F, Valadi H, Bossios A, Sjostrand M, Lotvall JO. Exosome–endothelial cell interactions: a novel therapeutic approach for heart failure? Cell Physiol Biochem. 2017;43(1):52–68.

170. Zhang J, Li Y. Therapeutic uses of FGFs. Semin Cell Dev Biol. 2016;53:144–54.

171. Arslan F, Lai RC, Lee MM, Smeets MB, Akeroyd L, Choo A, Aguor EN, et al. Insulin-like growth factor 1 receptor-dependent pathway drives epicardial adipose tissue differentiation. Mol Ther. 2015;13(12):2960–7.

172. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of vascular endothelial growth factor for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(12):2377–88.

173. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684–91.

174. Liang X, Liu T, Wang Z, Tan HH, et al. Cardiac progenitor cell-derived exosomes prevent cardiomyocyte apoptosis through exosomal miR-21 by targeting PDCD4. Cell Death Dis. 2016;7(6):e2277.

175. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(12):2377–88.

176. Zangi L, Lui KO, Zangi L, Oliveira MS, Ye LY, Ma Q, Sultana N, Hadas Y, et al. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease. Wiley Interdiscip Rev Syst Biol Med. 2017(9). https://doi.org/10.1002/wsbm.1367.

177. Zangi L, Oliveira MS, Ye LY, Ma Q, Sultana N, Hadas Y, et al. Insulin-like growth factor 1 receptor-dependent pathway drives epicardial adipose tissue formation after myocardial infarction. Circulation. 2017;135(15):1592–7.

178. Hadas Y, Katz MG, Bridges GR, Zangi L. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease. Wiley Interdiscip Rev Syst Biol Med. 2017(9). https://doi.org/10.1002/wsbm.1367.

179. Patel S, Athirasala A, Menezes PP, Ashwanikumar N, Zou T, Sahay G, et al. Messenger RNA delivery for tissue engineering and regenerative medicine applications. Tissue Eng Part A. 2015;21(2–3):91–112.

180. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of vascular endothelial growth factor for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(12):2377–88.

181. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of vascular endothelial growth factor for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(12):2377–88.
206. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5.

207. Ma Z, Wang Y, Li H. Applications of extracellular vesicles in tissue regeneration. Biomicrofluidics. 2020;14(1):011501.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.